GLP-1 Receptor Agonist Market by Product (Bydureon, Ozempic, Saxenda), Drug Class (Albiglutide, Dulaglutide, Exenatide), Route of Administration, Distribution Channel, Application - Global Forecast 2024-2030

GLP-1 Receptor Agonist Market by Product (Bydureon, Ozempic, Saxenda), Drug Class (Albiglutide, Dulaglutide, Exenatide), Route of Administration, Distribution Channel, Application - Global Forecast 2024-2030


The GLP-1 Receptor Agonist Market size was estimated at USD 4.44 billion in 2023 and expected to reach USD 4.92 billion in 2024, at a CAGR 11.26% to reach USD 9.38 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the GLP-1 Receptor Agonist Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the GLP-1 Receptor Agonist Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the GLP-1 Receptor Agonist Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., A-S Medication Solutions, LLC, Amgen Inc., AstraZeneca PLC, Biora Therapeutics, Inc., Eli Lilly and Company, Hanmi Pharm.Co., Ltd., Innovent Biologics (Suzhou) Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck KGaA, Novo Nordisk A/S, Optum, Inc., Paige Biomedicine (Suzhou) Co., Ltd., Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage



This research report categorizes the GLP-1 Receptor Agonist Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Bydureon
Ozempic
Saxenda
Trulicity
Victoza
Drug Class
Albiglutide
Dulaglutide
Exenatide
Liraglutide
Lixisenatide
Semaglutide
Route of Administration
Oral
Parenteral
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Application
Liver Cirrhosis
Non-Alcoholic Steatohepatitis
Obesity
Type 2 Diabetes Mellitus
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the GLP-1 Receptor Agonist Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the GLP-1 Receptor Agonist Market?
3. What are the technology trends and regulatory frameworks in the GLP-1 Receptor Agonist Market?
4. What is the market share of the leading vendors in the GLP-1 Receptor Agonist Market?
5. Which modes and strategic moves are suitable for entering the GLP-1 Receptor Agonist Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. GLP-1 Receptor Agonist Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the number of diabetic patients and recent advancement in the treatment of Type 2 Diabetes Mellitus
5.1.1.2. Growing number of approval for novel medications
5.1.1.3. Government awareness campaigns to curb diabetes mellitus
5.1.2. Restraints
5.1.2.1. Patent expiry of GLP-1 receptor agonist drugs
5.1.3. Opportunities
5.1.3.1. Rising new product launches and ongoing development of strong medication pipeline
5.1.3.2. Developing focus on the collaboration activities to obtain commercialization rights
5.1.4. Challenges
5.1.4.1. Severe risks and limitations such as renal impairment, pancreatitis, diabetic ketoacidosis
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. GLP-1 Receptor Agonist Market, by Product
6.1. Introduction
6.2. Bydureon
6.3. Ozempic
6.4. Saxenda
6.5. Trulicity
6.6. Victoza
7. GLP-1 Receptor Agonist Market, by Drug Class
7.1. Introduction
7.2. Albiglutide
7.3. Dulaglutide
7.4. Exenatide
7.5. Liraglutide
7.6. Lixisenatide
7.7. Semaglutide
8. GLP-1 Receptor Agonist Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. GLP-1 Receptor Agonist Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. GLP-1 Receptor Agonist Market, by Application
10.1. Introduction
10.2. Liver Cirrhosis
10.3. Non-Alcoholic Steatohepatitis
10.4. Obesity
10.5. Type 2 Diabetes Mellitus
11. Americas GLP-1 Receptor Agonist Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific GLP-1 Receptor Agonist Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. 9 Meters Biopharma, Inc.
15.1.2. A-S Medication Solutions, LLC
15.1.3. Amgen Inc.
15.1.4. AstraZeneca PLC
15.1.5. Biora Therapeutics, Inc.
15.1.6. Eli Lilly and Company
15.1.7. Hanmi Pharm.Co., Ltd.
15.1.8. Innovent Biologics (Suzhou) Ltd.
15.1.9. Jiangsu Hengrui Medicine Co., Ltd.
15.1.10. Merck KGaA
15.1.11. Novo Nordisk A/S
15.1.12. Optum, Inc.
15.1.13. Paige Biomedicine (Suzhou) Co., Ltd.
15.1.14. Pfizer Inc.
15.1.15. Sun Pharmaceutical Industries Limited
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
FIGURE 2. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2023 VS 2030
FIGURE 3. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLP-1 RECEPTOR AGONIST MARKET DYNAMICS
FIGURE 7. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 16. GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings